Quest Diagnostics Incorporated (DGX)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE
Market Cap: $28.85B
Last updated: Nov 17, 2026 at 4:24 PM ET
Quest Diagnostics Incorporated (DGX) Statistics
Quest Diagnostics (DGX) has a market cap of $28.85B and an enterprise value of $33.60B. Its trailing P/E of 23.2x is above its 10-year median of 16.5x.
Total Valuation
Enterprise value is 16.48% above the market cap, as debt exceeds cash.
| Market Cap | $28.85B |
|---|---|
| Enterprise Value | $33.60B |
| Latest price (Nov 17, 2026) | $256.36 |
Key Dates
The next earnings report is expected on Feb 8, 2027, covering the quarter ending Dec 31, 2026. The next ex-dividend date is Jan 12, 2027.
| Next Earnings Date | Feb 8, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 22, 2026 |
| Next Ex-Dividend Date | Jan 12, 2027 |
| Next Payment Date | Jan 27, 2027 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 2.4x and 3.7x. Its year-end P/E ranged from 10.7x to 17.9x from 2016 to 2025.
| P/E Ratio | 23.2x |
|---|---|
| Forward P/E | 22.4x |
| P/S Ratio | 2.4x |
| Forward P/S | 2.4x |
| P/B Ratio | 3.7x |
| P/FCF Ratio | 20.5x |
| P/OCF Ratio | 14.8x |
| PEG Ratio | 2.7 |
Enterprise Valuation
Counting debt and cash, the company is valued at 14.2x EBITDA and 24.0x free cash flow.
| EV / Earnings | 28.5x |
|---|---|
| EV / Sales | 2.8x |
| EV / EBITDA | 14.2x |
| EV / EBIT | 19.3x |
| EV / FCF | 24.0x |
Price Statistics
The stock is up 38.33% over 52 weeks and trades 5.99% above its 50-day average.
| Beta (1Y) | -0.06 |
|---|---|
| 52-Week Change | +38.33% |
| 1-Month Change | +9.13% |
| 3-Month Change | +6.44% |
| 6-Month Change | +35.72% |
| 5-Year Change | +71.56% |
| 10-Year Change | +209.21% |
| Total Return (1Y) | +40.16% |
| Total Return (3Y CAGR) | +25.53% |
| Total Return (5Y CAGR) | +13.45% |
| Return vs SPY (1Y) | +27.99% |
| Max Drawdown (1Y) | -11.89% |
| Max Drawdown (3Y) | -12.44% |
| Sharpe Ratio (1Y) | 1.41 |
| Correlation with SPY (1Y) | -0.03 |
| 50-Day Average | $241.88 |
| 200-Day Average | $215.45 |
| 52-Week Range | $168.34 to $263.19 |
| RSI (14 Days) | 59.9 |
| Average Volume (20 Days) | 953.33K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.70x current liabilities, and total debt is 0.73x shareholder equity.
| Current Ratio | 1.70x |
|---|---|
| Quick Ratio | 1.58x |
| Debt / Equity | 0.73x |
| Debt / EBITDA | 2.38x |
| Debt / FCF | 4.04x |
Returns and Efficiency
Return on invested capital is 10.19% over the last 12 months, against a 5-year average of 11.56%.
| Return on Equity (ROE) | 15.46% |
|---|---|
| Return on Assets (ROA) | 6.85% |
| Return on Invested Capital (ROIC) | 10.19% |
| Return on Capital Employed (ROCE) | 11.33% |
| ROE (5Y Average) | 18.42% |
| ROA (5Y Average) | 8.36% |
| ROIC (5Y Average) | 11.56% |
| Asset Turnover | 0.71x |
| Inventory Turnover | 35.12x |
| Receivables Turnover | 7.01x |
| Cash Conversion Cycle | -12 days |
Taxes
Income tax took 22.92% of pretax income over the last 12 months.
| Income Tax (TTM) | $342.00M |
|---|---|
| Effective Tax Rate | 22.92% |
Scores
DGX has an Altman Z-Score of 3.81, in the safe zone above 2.99, and a Piotroski F-Score of 8 of 9, in the strong band of 8 or 9.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 3.81 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 8 of 9 |
| Piotroski Strength | Strong |
Income Statement
Revenue of $11.84B over the last 12 months is up 9.13% from the 12 months before.
| Revenue | $11.84B |
|---|---|
| Revenue Growth (YoY) | +9.13% |
| Gross Profit | $3.92B |
| Operating Income | $1.72B |
| Pretax Income | $1.49B |
| Net Income | $1.18B |
| EBITDA | $2.33B |
| EBIT | $1.74B |
| Reported EPS (TTM) | $11.04 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 44.31% of the $17.22B in total assets.
| Cash and Equivalents | $797.00M |
|---|---|
| Total Debt | $5.55B |
| Net Debt | $4.75B |
| Net Debt Per Share | $43.21 |
| Working Capital | $1.28B |
| Shareholder Equity | $7.63B |
| Book Value Per Share | $69.38 |
| Tangible Book Value | -$3.11B |
| Total Assets | $17.22B |
| Total Liabilities | $9.19B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $576.00M of capital spending, operating cash flow left $1.38B of free cash flow.
| Operating Cash Flow | $1.95B |
|---|---|
| Capital Expenditures | $576.00M |
| Free Cash Flow | $1.38B |
| FCF Per Share | $12.46 |
| Depreciation and Amortization | $585.00M |
| Dividends Paid | $417.00M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 14.55%, against a 5-year average of 15.58%.
| Gross Margin | 33.11% |
|---|---|
| Operating Margin | 14.55% |
| Pretax Margin | 12.60% |
| Net Margin | 9.97% |
| EBITDA Margin | 19.66% |
| EBIT Margin | 14.72% |
| FCF Margin | 11.61% |
| Gross Margin (5Y Average) | 34.56% |
| Operating Margin (5Y Average) | 15.58% |
| Net Margin (5Y Average) | 11.63% |
Growth
Revenue grew 3.74% a year over 3 years, and EPS fell 0.24% a year.
| Revenue Growth (3Y CAGR) | +3.74% |
|---|---|
| Revenue Growth (5Y CAGR) | +3.18% |
| EPS Growth (3Y CAGR) | -0.24% |
| EPS Growth (5Y CAGR) | -2.45% |
| FCF Growth (3Y CAGR) | +1.13% |
| FCF Growth (5Y CAGR) | -3.05% |
| Operating Income Growth (3Y CAGR) | +2.90% |
| Book Value Per Share Growth (2Y CAGR) | +7.10% |
Dividends and Yields
DGX pays out 19.06% of earnings as dividends.
| Dividend Per Share (Annual) | $3.44 |
|---|---|
| Dividend Yield | 1.34% |
| Payment Schedule | Quarterly |
| Dividend Growth (3Y CAGR) | +6.61% |
| Dividend Growth (5Y CAGR) | +7.35% |
| Payout Ratio | 19.06% |
| FCF Payout Ratio | 30.33% |
| Earnings Yield | 4.31% |
| FCF Yield | 4.88% |
| Buyback Yield | 1.60% |
| Shareholder Yield | 3.07% |
Stock Splits
The last split was a 2-for-1 forward split on Jun 21, 2005.
| Last Split Date | Jun 21, 2005 |
|---|---|
| Split Type | Forward split |
| Split Ratio | 2:1 |
Peer Position
Against 11 similar companies, DGX has the 8th highest P/E and the 5th highest ROIC.
P/E RatioPeer median 28.4x
P/S RatioPeer median 6.0x
ROICPeer median 8.20%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +6.27%
Dividend YieldPeer median 0.00%
| P/E Ratio | 23.2x vs 28.4x median |
|---|---|
| P/S Ratio | 2.4x vs 6.0x median |
| ROIC | 10.19% vs 8.20% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +9.13% vs +6.27% median |
| Dividend Yield | 1.34% vs 0.00% median |
Analyst Forecast
Consensus estimates put revenue growth at 6.95% and EPS growth at 10.30% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +6.95% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +10.30% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About DGX
What is DGX's market cap?
Quest Diagnostics has a market cap of $28.85B. Its enterprise value, which adds debt and subtracts cash, is $33.60B.
What is DGX's P/E ratio?
Quest Diagnostics has a trailing P/E ratio of 23.2x and a forward P/E of 22.4x.
How many shares of DGX are outstanding?
Quest Diagnostics has 110.00M shares outstanding. The count is down 1.79% from a year earlier.
Does DGX pay a dividend?
Yes. Quest Diagnostics pays $3.44 a share a year, a dividend yield of 1.34%.
How much debt does DGX have?
Quest Diagnostics has $5.55B of total debt and $797.00M of cash and equivalents, a net debt position of $4.75B.
DGX pages: Overview, Dividends, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts